Why did Dexcom's margins decline so much in Q4 2024?

Non-GAAP gross margin fell to 59.4% from 64.2%, and non-GAAP operating margin fell to 18.8% from 23.5%. Operating expenses rose, with SG&A up 8% and R&D up 2% year over year, while revenue growth slowed. The filing also cites business transition items, including a non-cash inventory build charge, and the mix shift away from hardware, which carries lower revenue. The filing does not fully break down the drivers of the gross margin decline, so investors should review the 10-K and earnings call commentary.

Is the 2025 guidance realistic given the Q4 2024 margin levels?

The guidance implies a meaningful margin recovery. Non-GAAP gross margin of 64% to 65% compares with 59.4% in Q4 2024 and 2024's full-year level of about 61.8%. Non-GAAP operating margin of about 21% compares with 18.8% for both Q4 and the full year. Revenue guidance of $4.60 billion implies about 14% growth, versus 11% in 2024 and 8% in Q4. Achieving this depends on continued sensor growth, international expansion, and cost discipline after the 2024 sales force expansion.

What does the $1.2 billion reclassification of convertible notes mean for investors?

The current portion of long-term senior convertible notes rose to $1.204 billion from zero a year earlier, meaning these notes come due within the next twelve months. Dexcom had $2.58 billion in cash, cash equivalents and marketable securities and an undrawn revolving credit facility, so it appears well positioned to repay them from existing liquidity. Investors should still watch how the company addresses the maturity, including whether it repays in cash, refinances, or settles through equity.

How strong is growth outside the United States?

International revenue is the faster-growing segment. It rose 17% reported and 19% organic in Q4 2024, and 15% reported and 17% organic for the full year. U.S. revenue grew 4% in Q4 and 10% for the full year. International revenue was about 28% of full-year sales. Recent drivers include reimbursement for Dexcom ONE+ in France and the expansion of CGM access in other markets.

Why do GAAP and non-GAAP results differ so much, and which should investors focus on?

Non-GAAP adjustments exclude amortization of acquired intangibles, business transition costs, intellectual property litigation costs (primarily against Abbott), share-based compensation in Adjusted EBITDA, and tax items. In Q4 2024, GAAP operating income was $188.9 million versus $209.5 million non-GAAP, and GAAP diluted EPS was $0.38 versus $0.45 non-GAAP. The company has recurring IP litigation costs, and share-based compensation is a real economic expense, so investors should weigh GAAP results alongside non-GAAP measures rather than relying on either alone.

DXCM 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 13, 2025. Cited figures are marked; the original filing is the authoritative source.

Dexcom reported fourth-quarter and full-year 2024 results that show continued top-line growth alongside significant margin compression.

Q4 revenue rose 8% year over year to $1.114 billion^a (8% organic), a sharp slowdown from 27% growth in Q4 2023. Full-year revenue grew 11% to $4.033 billion (12% organic). U.S. revenue grew 4% in Q4, while international revenue grew 17% reported and 19% organic.

Sensor and other revenue increased 13%^b in Q4, offset by a 49% decline in hardware revenue. Profitability weakened materially. Q4 non-GAAP operating margin fell 470 basis points to 18.8%, and non-GAAP gross margin fell to 59.4% from 64.2%.

Q4 GAAP diluted EPS was $0.38^c versus $0.62 a year earlier, and non-GAAP diluted EPS was $0.45 versus $0.50. Full-year non-GAAP operating margin was 18.8%, down 100 basis points, and Adjusted EBITDA was $1.105 billion. Management attributed part of the Q4 pressure to a non-cash inventory build charge and related business transition items, but the margin trend is the central concern for investors.

Dexcom reiterated 2025 guidance for revenue of $4.60 billion^d (about 14% growth), non-GAAP gross margin of 64% to 65%, and non-GAAP operating margin of about 21%, and added Adjusted EBITDA margin guidance of about 30%. The implied margin recovery is substantial relative to Q4 2024 exit rates. The company ended 2024 with $2.58 billion in cash, cash equivalents and marketable securities and an undrawn revolver, but $1.20 billion of convertible notes were reclassified to current liabilities, creating a near-term refinancing or repayment item to monitor.

02—Key points

Key Highlights

Q4 2024 revenue rose 8% year over year to $1.114 billion, a sharp deceleration from 27% growth in Q4 2023; full-year revenue grew 11% to $4.033 billion.
Sensor and other revenue grew 13% in Q4 and 18% for the year, while hardware revenue fell 49% in Q4 and 43% for the year.
International revenue grew 17% reported (19% organic) in Q4, while U.S. revenue grew only 4%.
Q4 non-GAAP operating margin declined 470 basis points to 18.8%, and non-GAAP gross margin fell to 59.4% from 64.2%.
Q4 GAAP diluted EPS was $0.38 (vs. $0.62) and non-GAAP diluted EPS was $0.45 (vs. $0.50); full-year non-GAAP diluted EPS was $1.64 (vs. $1.52).
2025 guidance reiterates revenue of $4.60 billion (about 14% growth) and non-GAAP operating margin of about 21%, and adds Adjusted EBITDA margin guidance of about 30%.
Liquidity was $2.58 billion in cash and marketable securities with an undrawn revolver, but $1.20 billion of convertible notes moved to current liabilities.

03—Questions

Frequently Asked Questions

Why did Dexcom's margins decline so much in Q4 2024?
Non-GAAP gross margin fell to 59.4% from 64.2%, and non-GAAP operating margin fell to 18.8% from 23.5%. Operating expenses rose, with SG&A up 8% and R&D up 2% year over year, while revenue growth slowed. The filing also cites business transition items, including a non-cash inventory build charge, and the mix shift away from hardware, which carries lower revenue. The filing does not fully break down the drivers of the gross margin decline, so investors should review the 10-K and earnings call commentary.
Is the 2025 guidance realistic given the Q4 2024 margin levels?
The guidance implies a meaningful margin recovery. Non-GAAP gross margin of 64% to 65% compares with 59.4% in Q4 2024 and 2024's full-year level of about 61.8%. Non-GAAP operating margin of about 21% compares with 18.8% for both Q4 and the full year. Revenue guidance of $4.60 billion implies about 14% growth, versus 11% in 2024 and 8% in Q4. Achieving this depends on continued sensor growth, international expansion, and cost discipline after the 2024 sales force expansion.
What does the $1.2 billion reclassification of convertible notes mean for investors?
The current portion of long-term senior convertible notes rose to $1.204 billion from zero a year earlier, meaning these notes come due within the next twelve months. Dexcom had $2.58 billion in cash, cash equivalents and marketable securities and an undrawn revolving credit facility, so it appears well positioned to repay them from existing liquidity. Investors should still watch how the company addresses the maturity, including whether it repays in cash, refinances, or settles through equity.
How strong is growth outside the United States?
International revenue is the faster-growing segment. It rose 17% reported and 19% organic in Q4 2024, and 15% reported and 17% organic for the full year. U.S. revenue grew 4% in Q4 and 10% for the full year. International revenue was about 28% of full-year sales. Recent drivers include reimbursement for Dexcom ONE+ in France and the expansion of CGM access in other markets.
Why do GAAP and non-GAAP results differ so much, and which should investors focus on?
Non-GAAP adjustments exclude amortization of acquired intangibles, business transition costs, intellectual property litigation costs (primarily against Abbott), share-based compensation in Adjusted EBITDA, and tax items. In Q4 2024, GAAP operating income was $188.9 million versus $209.5 million non-GAAP, and GAAP diluted EPS was $0.38 versus $0.45 non-GAAP. The company has recurring IP litigation costs, and share-based compensation is a real economic expense, so investors should weigh GAAP results alongside non-GAAP measures rather than relying on either alone.

04—Continue

← View all 8-K filings